Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Biotech
Sanofi crosses Sjögren’s off $5B drug’s hit list after phase 2
Sanofi axed Sjögren’s from the list of targeted indications for frexalimab—and reported a phase 3 flop for one of its tarnished former top prospects.
Nick Paul Taylor
Apr 25, 2024 2:35am
Big Pharma ROI for drug R&D saw surprise rebound in 2023: report
Apr 25, 2024 12:01am
Sponsored
Cloud-Based Technology Supports Complex Supply Chains
Apr 22, 2024 8:00am
Cidara regains rights to flu med from Janssen, divests Rezzayo
Apr 24, 2024 4:05pm
Sponsored
Patient Access and Affordability: PhRMA shares how we can put patients first
Feb 12, 2024 8:00am
To be better at neuroscience, Biogen will invest elsewhere
Apr 24, 2024 10:37am